Prostate Cancer Quarterly Benchmarks Report

Fiscal Year 2011 4th Quarter Report

Jurisdiction/Program: ALL

Sponsor: CRF

			Period:	7/1-9/30	10/1-12/31	1/1-3/31	4/1-6/30	7/1/-6/30
			Run Date:	01/13/2011	04/13/2011	07/01/2011	10/04/2011	10/04/2011
Category	No.	Indicator	Standard	FY11 1Q	FY11 2Q	FY11 3Q	FY11 4Q	FY11 Total
Screening Priority Population	1	Percent of prostate cancer screenngs with both PSA and DRE	≥80%	100.0	96.3	96.9	100.0	96.8
Case Management Among Program-eligible Clients	2	Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with a diagnosis status of 'Complete'	≥80%	100.0	90.0	100.0	66.7	95.0
	3	Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with date of diagnosis within 90 days of screening among those with diagnosis status of 'Complete'	≥80%	100.0	88.9	100.0	50.0	78.9
	4	Percent of prostate cancers diagnosed with treatment started	≥80%	100.0	0.0	40.0	66.7	70.0
	5	Percent of prostate cancers with treatment started within 60 days of diagnosis among those who started treatment	≥80%	100.0	No Data	100.0	0.0	57.1
	6	Percent of prostate cancers with stage information among clients diagnosed with cancer who had surgery	≥80%	100.0	80.0	100.0	40.0	50.0
Notification	7	Percent of PSA results received by the program within 28 days of test	≥80%	100.0	98.5	98.4	95.8	98.0
	8	Percent of men ever notified of screening* results by program	≥95%	95.2	95.2	100.0	100.0	99.5
	9	Percent of men with abnormal findings/needs further evaluation to rule out cancer, were notifed of results, and were notified by program within 7 days of when screening^ results received by program	≥80%	33.3	36.4	75.0	75.0	51.7

*Screening means screened with Prostate Specific Antigen (PSA) and/or Digital Rectal Exam (DRE) *Screening means screened with Prostate Specific Antigen (PSA) or PSA and Digital Rectal Exam (DRE)